Vaspin in obesity and diabetes: Pathophysiological and clinical significance

Endocrine

Volumn 41, Issue 2, 2012, Pages 176-182

  Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adipokines; Obesity; Type 2 diabetes; Vaspin; Visceral obesity

Indexed keywords

ATORVASTATIN; RECOMBINANT HORMONE; RECOMBINANT VASPIN; UNCLASSIFIED DRUG; VASPIN;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; EXERCISE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; WEIGHT REDUCTION;

EID: 84862690761     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9572-0     Document Type: Review

References (58)

1. E.E. Kershaw, J.S. Flier, Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556 (2004) (Pubitemid 38766330)
2. N.E. Gulcelik, A. Usman, A. Gürlek, Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 36, 397-403 (2009)
3. M. Blüher, Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117, 241-250 (2009)
4. H.E. Bays, "Sick fat," metabolic disease, and atherosclerosis. Am. J. Med. 122, S26-S37 (2009)
5. S. Kralisch, M. Blüher, R. Paschke, M. Stumvoll, M. Fasshauer, Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev. Med. Chem. 7, 39-45 (2007) (Pubitemid 46062372)
6. L.F. Van Gaal, I.L. Mertens, C.E. DeBlock, Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880 (2006) (Pubitemid 46028447)
7. M. Blüher, The inflammatory process of adipose tissue. Pediatr. Endocrinol. Rev. 6, 24-31 (2008)
8. G.S. Hotamisligil, Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes 107, 119-125 (1999)
9. A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Natl. Rev. Mol. Cell. Biol. 9, 367-377 (2008) (Pubitemid 351574198)
10. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994) (Pubitemid 24365442)
11. R.S. Ahima, J.S. Flier, Leptin. Annu. Rev. Physiol. 62, 413-437 (2000)
12. H. Chen, O. Charlat, L.A. Tartaglia, E.A. Woolf, X. Weng, S.J. Ellis, N.D. Lakey, J. Culpepper, K.J. Moore, R.E. Breitbart, G.M. Duyk, R.I. Tepper, J.P. Morgenstern, Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491-495 (1996) (Pubitemid 26060722)
13. K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37, 11-32 (2010)
14. M.E. Trujillo, P.E. Scherer, Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257, 167-175 (2005) (Pubitemid 40193966)
15. I. Castan-Laurell, C. Dray, C. Attané, T. Duparc, C. Knauf, P. Valet, Apelin, diabetes, and obesity. Endocrine 40, 1-9 (2011)
16. K. Hida, J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, Y.S. Kanwar, Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. USA 102, 10610-10615 (2005) (Pubitemid 41061602)
17. J. Wada, Vaspin and insulin resistance. Rinsho Byori 56, 705-711 (2008)
18. N. Klöting, P. Kovacs, M. Kern, J.T. Heiker, M. Fasshauer, M.R. Schön, M. Stumvoll, A.G. Beck-Sickinger, M. Blüher, Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 54, 1819-1823 (2011)
19. P.G. Gettins, Serpin structure, mechanism, and function. Chem. Rev. 102, 4751-4804 (2002)
20. R.H. Law, Q. Zhang, S. MacGowan, A.M. Buckle, G.A. Silverman, W. Wong, C.J. Rosado, C.G. Langendorf, R.N. Pike, P.I. Bird, J.C. Whisstock, An overview of the serpin superfamily. Genome Biol. 7, 216 (2006)
21. G.A. Silverman, P.I. Bird, R.W. Carrell, F.C. Church, P.B. Coughlin, P.G. Gettins, J.A. Irving, D.A. Lomas, C.J. Luke, R.W. Moyer, P.A. Pemberton, E. Remold-O'Donnell, G.S. Salvesen, J. Travis, J.C. Whisstock, The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293-33296 (2001)
22. K. Kempf, B. Rose, T. Illig, W. Rathmann, K. Strassburger, B. Thorand, C. Meisinger, H.E. Wichmann, C. Herder, C. Vollmert, Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp. Clin. Endocrinol. Diabetes 118, 184-189 (2010)
23. N. Klöting, J. Berndt, S. Kralisch, P. Kovacs, M. Fasshauer, M.R. Schön, M. Stumvoll, M. Blüher, Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339, 430-436 (2006) (Pubitemid 41697566)
24. A. Körner, M. Neef, D. Friebe, S. Erbs, J. Kratzsch, K. Dittrich, S. Blüher, T.M. Kapellen, P. Kovacs, M. Stumvoll, M. Blüher, W. Kiess, Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. (Lond.) 35, 578-586 (2011)
25. J.N. Fain, B. Buehrer, S.W. Bahouth, D.S. Tichansky, A.K. Madan, Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism 57, 1005-1015 (2008) (Pubitemid 351814693)
26. U. Meyer-Hoffert, Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch. Immunol. Ther. Exp. 57, 345-354 (2009)
27. B.S. Youn, N. Klöting, J. Kratzsch, N. Lee, J.W. Park, E.S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, M. Blü- her, Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57, 372-377 (2008)
28. C. von Loeffelholz, M. Möhlig, A.M. Arafat, F. Isken, J. Spranger, K. Mai, H.S. Randeva, A.F. Pfeiffer, M.O. Weickert, Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur. J. Endocrinol. 162, 507-513 (2010)
29. G. Aust, O. Richter, S. Rohm, C. Kerner, J. Hauss, N. Klöting, K. Ruschke, B.S. Youn, M. Blüher, Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 204, 262-266 (2009)
30. A. Handisurya, M. Riedl, G. Vila, C. Maier, M. Clodi, T. Prikoszovich, B. Ludvik, G. Prager, A. Luger, A. Kautzky-Willer, Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes. Surg. 20, 198-203 (2010)
31. B.L. Tan, D. Heutling, J. Chen, S. Farhatullah, R. Adya, S.D. Keay, C.R. Kennedy, H. Lehnert, H.S. Randeva, Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 57, 1501-1507 (2008)
32. N.E. Gulcelik, J. Karakaya, A. Gedik, A. Usman, A. Gurlek, Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur. J. Endocrinol. 160, 65-70 (2009)
33. J. Seeger, M. Ziegelmeier, A. Bachmann, U. Lössner, J. Kratzsch, M. Blüher, M. Stumvoll, M. Fasshauer, Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J. Clin. Endocrinol. Metab. 93, 247-251 (2008)
34. N.P. Kadoglou, A. Kapelouzou, H. Tsanikidis, I. Vitta, C.D. Liapis, N. Sailer, Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 119, 63-68 (2011)
35. S. Akbarzadeh, I. Nabipour, S.M. Jafari, A. Movahed, N. Motamed, M. Assadi, N. Hajian, Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. (2011). doi:10.1016/j.diabres.2011.10.004
36. N. Cinar, N.E. Gülçelik, K. Aydín, S. Akín, A. Usman, A. Gürlek, Serum vaspin levels in hypothyroid patients. Eur. J. Endocrinol. 165, 563-569 (2011)
37. J.A. Lee, H.S. Park, Y.S. Song, Y.J. Jang, J.H. Kim, Y.J. Lee, Y.S. Heo, Relationship between vaspin gene expression and abdominal fat distribution of Korean women. Endocr. J. 8, 639-646 (2011)
38. N. Klöting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schön, M. Kern, M. Stumvoll, M. Blüher, Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506-E515 (2010)
39. H.L. Li, W.H. Peng, S.T. Cui, H. Lei, Y.D. Wei, W.M. Li, Y.W. Xu, Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin. Chem. Lab. Med. 49, 1547-1554 (2011)
40. N.P. Kadoglou, A. Gkontopoulos, A. Kapelouzou, G. Fotiadis, E.K. Theofilogiannakos, G. Kottas, S. Lampropoulos, Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin. Chim. Acta 412, 48-52 (2011)
41. Y. Yilmaz, R. Kurt, A. Gurdal, Y.O. Alahdab, O. Yonal, E. Senates, N. Polat, F. Eren, N. Imeryuz, H. Oflaz, Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 217, 125-129 (2011)
42. S.G. Spiroglou, C.G. Kostopoulos, J.N. Varakis, H.H. Papadaki, Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 17, 115-130 (2010)
43. C.H. Jung, W.J. Lee, J.Y. Hwang, S.M. Seol, Y.M. Kim, Y.L. Lee, J.Y. Park, Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 413, 264-269 (2011)
44. N.P. Kadoglou, I.S. Vrabas, A. Kapelouzou, S. Lampropoulos, N. Sailer, A. Kostakis, C.D. Liapis, Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regul. Pept. 170, 57-61 (2011)
45. J.K. Cho, T.K. Han, H.S. Kang, Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur. J. Appl. Physiol. 108, 347-353 (2010)
46. S.M. Kim, G.J. Cho, M. Yannakoulia, T.G. Hwang, I.H. Kim, E.K. Park, C.S. Mantzoros, Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism 60, 1294-1299 (2011)
47. A. Oberbach, K. Kirsch, S. Lehmann, N. Schlichting, M. Fasshauer, K. Zarse, M. Stumvoll, M. Ristow, M. Blüher, P. Kovacs, Serum vaspin concentrations are decreased after exercise-induced oxidative stress. Obes. Facts 3, 328-331 (2010)
48. M. Ristow, K. Zarse, A. Oberbach, N. Klöting, M. Birringer, M. Kiehntopf, M. Stumvoll, C.R. Kahn, M. Blüher, Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA 106, 8665-8670 (2009)
49. A. Tönjes, M. Fasshauer, J. Kratzsch, M. Stumvoll, M. Blüher, Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS ONE 5, e13911 (2010)
50. E. Jeong, B.S. Youn, D.W. Kim, E.H. Kim, J.W. Park, C. Namkoong, J.Y. Jeong, S.Y. Yoon, J.Y. Park, K.U. Lee, M.S. Kim, Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J. Clin. Endocrinol. Metab. 95, 1869-1875 (2010)
51. L. Brunetti, C. Di Nisio, L. Recinella, A. Chiavaroli, S. Leone, C. Ferrante, G. Orlando, M. Vacca, Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 32, 1866-1871 (2011)
52. L.J. Aronne, T. Wadden, K.K. Isoldi, K.A. Woodworth, When prevention fails: obesity treatment strategies. Am. J. Med. 122, S24-S32 (2009)
53. I. Shai, D. Schwarzfuchs, Y. Henkin, D.R. Shahar, S. Witkow, I. Greenberg, R. Golan, D. Fraser, A. Bolotin, H. Vardi, O. Tangi- Rozental, R. Zuk-Ramot, B. Sarusi, D. Brickner, Z. Schwartz, E. Sheiner, R. Marko, E. Katorza, J. Thiery, G.M. Fiedler, M. Blüher, M. Stumvoll, M.J. Stampfer, Weight loss with a lowcarbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229-241 (2008) (Pubitemid 352008438)
54. M. Blüher, A. Rudich, N. Klöting, R. Golan, Y. Henkin, E. Rubin, D. Schwarzfuchs, Y. Gepner, M. J. Stampfer, M. Fiedler, J. Thiery, M. Stumvoll, I. Shai, Two patterns of adipokine and other biomarker dynamics in a long term weight loss intervention. Diabetes Care (2011, in press)
55. E. Koiou, K. Tziomalos, K. Dinas, I. Katsikis, E. Kalaitzakis, D. Delkos, E.A. Kandaraki, D. Panidis, The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr. J. 58, 237-246 (2011)
56. G.A. Martos-Moreno, J. Kratzsch, A. Körner, V. Barrios, F. Hawkins, W. Kiess, J. Argente, Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int. J. Obes. (Lond.) 35, 1355-1362 (2011)
57. H.M. Chang, H.J. Lee, H.S. Park, J.H. Kang, K.S. Kim, Y.S. Song, Y.J. Jang, Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity 18, 2105-2110 (2010)
58. E.S. Kang, F. Magkos, E. Sienkiewicz, C.S. Mantzoros, Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans. Eur. J. Endocrinol. 164, 911-917 (2011)